TrialCancer chemotherapy and pharmacology2017

A non-randomized, open-label, single-arm, Phase 2 study of emibetuzumab in Asian patients with MET diagnostic positive, advanced gastric cancer.

Daisuke Sakai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.